Biocon Biologics Ltd., a subsidiary of Biocon Ltd. has completed its multi-billion-dollar acquisition of the global biosimilars business of its partner Viatris Inc.

 

Biocon Biologics will recognize the combined revenue and associated profits from the acquired biosimilars products. The acquisition provides Biocon with direct commercial capabilities and supporting infrastructure in the advanced markets and several emerging markets.

 

With this acquisition Biocon Biologics becomes a leading global biosimilars player with eight commercialized products. Biocon Biologics has full ownership of its collaboration assets, bTrastuzumab, bPegfilgrastim, bBevacizumab, bGlargine, bAspart, bPertuzumab and bGlargine 300U, as well as Viatris’ rights for the in-licensed immunology products of bAdalimumab and bEtanercept. Biocon Biologics has also exercised the option to acquire Viatris’ rights for bAflibercept.

 

Biocon Biologics also has a unique portfolio of 20 biosimilar assets, including insulins and monoclonal antibodies.

Watch video >>>